Free Trial

Best Pharmaceutical Stocks To Follow Today - March 23rd

Pfizer logo with Medical background
Remove Ads

Pfizer, Merck & Co., Inc., and Eli Lilly and Company are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies involved in researching, developing, manufacturing, and marketing medications and healthcare products. These stocks can be influenced by regulatory approvals, clinical trial outcomes, patent expirations, and overall market trends in the healthcare sector. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Pfizer stock traded up $0.01 during trading hours on Friday, hitting $26.20. 349,778,786 shares of the stock were exchanged, compared to its average volume of 36,645,908. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $148.61 billion, a P/E ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer has a 12 month low of $24.48 and a 12 month high of $31.54. The business's 50-day moving average is $26.17 and its two-hundred day moving average is $27.04.

Read Our Latest Research Report on PFE

Remove Ads

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Merck & Co., Inc. stock traded down $1.29 during trading hours on Friday, hitting $93.44. 68,284,470 shares of the stock were exchanged, compared to its average volume of 10,227,995. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The stock has a market capitalization of $236.03 billion, a P/E ratio of 13.88, a P/E/G ratio of 0.77 and a beta of 0.35. Merck & Co., Inc. has a 12 month low of $81.04 and a 12 month high of $134.63. The business's 50-day moving average is $93.00 and its two-hundred day moving average is $101.07.

Read Our Latest Research Report on MRK

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Eli Lilly and Company stock traded down $3.13 during trading hours on Friday, hitting $839.44. 5,957,460 shares of the stock were exchanged, compared to its average volume of 3,151,645. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $795.93 billion, a P/E ratio of 71.69, a P/E/G ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The business's 50-day moving average is $835.99 and its two-hundred day moving average is $839.05.

Read Our Latest Research Report on LLY

Read More

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

The Future of Healthcare: 3 AI Stocks Leading the Way

The Future of Healthcare: 3 AI Stocks Leading the Way

2025 promises explosive growth for AI, but which companies are making a difference in healthcare? Chris Markoch highlights three stocks leading the charge.

Recent Videos

Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?
Why Palantir’s Future Just Got a Massive Boost

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads